Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Oncol ; 19(3): 461-4, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18006892

ABSTRACT

BACKGROUND: A randomized controlled trial showed longer overall survival (OS) with docetaxel compared with paclitaxel in metastatic breast cancer patients with prior exposure to anthracycline. We report a similar comparison using population-based data. METHODS: Data on patients treated with single-agent paclitaxel or docetaxel were retrospectively reviewed. OS was compared using a two-tailed log-rank test and expressed as Kaplan-Meier plots. A cost-effectiveness analysis was carried out using cost/patient and OS. RESULTS: Four hundred and thirty-five patients met eligibility criteria. Prognostic factors were balanced between docetaxel and paclitaxel groups. Median OS was significantly longer for docetaxel versus paclitaxel [10.9 versus 8.3 months; hazard ratio 0.76; 95% confidence interval (CI), 0.62-0.92; P = 0.006]. The median number of cycles administered were four (docetaxel) and three (paclitaxel). The incremental cost-effectiveness ratio was $2434/per month of median survival gained. In the sensitivity analysis, the results were robust except that paclitaxel dominated when the low end of the 95% CI of survival for docetaxel was compared with the high end for paclitaxel. CONCLUSION: This population-based study corroborated the randomized trial's conclusion that for patients with metastatic breast cancer, docetaxel provided superior survival compared with paclitaxel. Each additional month of survival had an incremental cost of $2434.


Subject(s)
Antineoplastic Agents/economics , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Paclitaxel/economics , Taxoids/economics , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Bone Neoplasms/secondary , Breast Neoplasms/economics , British Columbia/epidemiology , Cost-Benefit Analysis , Docetaxel , Drug Costs , Female , Humans , Middle Aged , Paclitaxel/therapeutic use , Retrospective Studies , Survival Rate , Taxoids/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...